Pediatric thromboembolism: a national survey in Japan

Akira Ishiguro1,2, Chibueze Chioma Ezinne3, Nobuaki Michihata4

  • 1Division of Hematology, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. ishiguro-a@ncchd.go.jp.

Insights

Pediatric thromboembolism is rising. Congenital thrombophilia, including protein C, S, and antithrombin defects, was identified in 19.3% of Japanese children, leading to earlier onset and more frequent recurrence.

Area of Science:

  • Pediatric Hematology
  • Thrombophilia Research
  • Epidemiology

Background:

  • Thromboembolism (blood clots) is increasingly diagnosed in children.
  • The prevalence of pediatric thrombophilia varies globally and was previously unquantified in Japan.

Purpose of the Study:

  • To investigate the incidence and characteristics of symptomatic thromboembolism in Japanese children.
  • To identify the prevalence of congenital thrombophilia and associated risk factors in this population.

Main Methods:

  • A nationwide survey was conducted among pediatric departments and specialists in Japan.
  • Data were collected on pediatric patients diagnosed with symptomatic thromboembolism between 2006 and 2010.
  • Eligible cases were analyzed for congenital and non-congenital causes of thrombophilia.

Main Results:

  • Congenital thrombophilia was identified in 19.3% of cases (n=54), primarily involving defects in protein C, protein S, and antithrombin.
  • Unlike in Caucasians, mutations in factor V Leiden and prothrombin G20210A were absent.
  • Children with congenital thrombophilia experienced earlier thromboembolism onset, higher consanguinity rates, and increased recurrence and post-thrombotic syndromes.
  • Non-congenital causes included congenital heart disease, central venous catheters, nephrotic syndrome, antiphospholipid syndrome, and malignancy.

Conclusions:

  • This study presents the first comprehensive data on pediatric thromboembolism and thrombophilia in Japan.
  • Congenital thrombophilia significantly impacts disease presentation, recurrence, and long-term outcomes in children.
  • Optimized management strategies are crucial given the high rates of recurrence and sequelae.

Related Concept Videos

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
618
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
419
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
636
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
351
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
312